Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
McKinsey
Baxter
Daiichi Sankyo
Chubb
Harvard Business School
Colorcon
Federal Trade Commission
Cipla

Generated: April 24, 2018

DrugPatentWatch Database Preview

PHOTREXA Drug Profile

« Back to Dashboard

Which patents cover Photrexa, and what generic alternatives are available?

Photrexa is a drug marketed by Avedro Inc and is included in one NDA.

The generic ingredient in PHOTREXA is riboflavin 5'-phosphate sodium. There are ten drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the riboflavin 5'-phosphate sodium profile page.
Summary for PHOTREXA
You have an error in your SQL syntax; check the manual that corresponds to your MariaDB server version for the right syntax to use near 'SODIUM') AND hsdb_drugname IS NOT NULL' at line 1
US Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 31
Clinical Trials: 1
Patent Applications: 2,506